Published in Neoplasia on February 01, 2011
Functions of S100 proteins. Curr Mol Med (2013) 2.43
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
S100 proteins in cancer. Nat Rev Cancer (2015) 1.35
Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene (2012) 1.04
RAGE mediates S100A4-induced cell motility via MAPK/ERK and hypoxia signaling and is a prognostic biomarker for human colorectal cancer metastasis. Oncotarget (2014) 1.03
Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating β-catenin. Acta Pharmacol Sin (2012) 0.99
Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. Cancer Lett (2014) 0.92
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (2012) 0.89
Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Int J Cancer (2012) 0.88
Systemic shRNA mediated knock down of S100A4 in colorectal cancer xenografted mice reduces metastasis formation. Oncotarget (2012) 0.87
Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1). Acta Pharmacol Sin (2011) 0.86
MicroRNA and cancer chemoprevention. Cancer Prev Res (Phila) (2013) 0.86
Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer (2012) 0.84
SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival. Oncogene (2015) 0.82
A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer (2015) 0.79
S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance. BMC Cancer (2015) 0.79
S100A4 in Cancer Metastasis: Wnt Signaling-Driven Interventions for Metastasis Restriction. Cancers (Basel) (2016) 0.79
Cancer subclonal genetic architecture as a key to personalized medicine. Neoplasia (2013) 0.78
Role of S100 Proteins in Colorectal Carcinogenesis. Gastroenterol Res Pract (2016) 0.78
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Med (2016) 0.77
The interconnectedness of cancer cell signaling. Neoplasia (2011) 0.75
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers. Cancers (Basel) (2016) 0.75
Modulating the wnt signaling pathway with small molecules. Protein Sci (2017) 0.75
Identification of c-MYC as a target of the APC pathway. Science (1998) 24.25
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34
Linking colorectal cancer to Wnt signaling. Cell (2000) 11.58
Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst (2004) 10.61
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) (2008) 5.82
New signals from the invasive front. Nature (2006) 5.51
Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov (2006) 5.29
Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell (2004) 4.98
Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A (1997) 3.79
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
S100A4 and metastasis: a small actor playing many roles. Am J Pathol (2009) 2.80
S100A4, a mediator of metastasis. J Biol Chem (2005) 2.68
Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res (2005) 1.89
beta-Catenin signaling in biological control and cancer. J Cell Biochem (2007) 1.89
Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res (2002) 1.82
The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer (2005) 1.78
Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res (2002) 1.78
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer Res (1997) 1.68
Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem (2008) 1.67
S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res (1999) 1.67
Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer (2004) 1.54
Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther (2003) 1.49
Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer (2005) 1.48
Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene (1996) 1.48
Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene (1996) 1.45
Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol (2009) 1.44
Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene (1997) 1.43
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res (2003) 1.41
Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology (2002) 1.38
Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res (2008) 1.36
Colon cancer--understanding how NSAIDs work. N Engl J Med (2006) 1.32
The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther (2005) 1.29
Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res (2007) 1.28
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol (2003) 1.23
Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets (2007) 1.23
Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis (2003) 1.21
Metastasis promoter S100A4 is a potentially valuable molecular target for cancer therapy. Cancer Lett (2008) 1.18
S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes. Br J Cancer (2002) 1.10
Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol (2008) 1.06
Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer (2004) 1.03
S100 alpha, CAPL, and CACY: molecular cloning and expression analysis of three calcium-binding proteins from human heart. Biochemistry (1992) 1.01
Overexpression of S100A4 is closely associated with progression of colorectal cancer. World J Gastroenterol (2005) 1.01
Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev (2005) 0.97
Selecting targets for cancer prevention: where do we go from here? Nat Rev Cancer (2006) 0.96
Wnt up your mind - intervention strategies for S100A4-induced metastasis in colon cancer. Gen Physiol Biophys (2009) 0.95
Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm Res (2009) 0.92
Metastasis-associated protein S100A4--a potential prognostic marker for colorectal cancer. J Surg Oncol (2006) 0.91
Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia (1999) 0.90
Enhanced S100A4 protein expression is clinicopathologically significant to metastatic potential and p53 dysfunction in colorectal cancer. Oncol Rep (2009) 0.88
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol Cancer Ther (2008) 0.87
beta-Catenin-mediated signaling: a novel molecular target for chemoprevention with anti-inflammatory substances. Biochim Biophys Acta (2005) 0.85
Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab (2006) 0.83
Subcellular distribution of S100A4 and its transcriptional regulation under hypoxic conditions in gastric cancer cell line BGC823. Cancer Sci (2010) 0.82
Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. J Natl Cancer Inst (2008) 0.81
Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol (2002) 8.60
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet (2003) 3.89
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med (2008) 3.00
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res (2002) 2.97
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol (2010) 2.66
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res (2005) 2.49
Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst (2011) 2.11
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg (2007) 1.79
A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth. Cancer Res (2011) 1.74
Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood (2005) 1.74
The metastasis-associated gene S100A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. Gastroenterology (2006) 1.73
S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell (2011) 1.71
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res (2004) 1.70
MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol (2005) 1.69
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood (2005) 1.69
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther (2009) 1.67
Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett (2008) 1.54
Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors. Appl Opt (2003) 1.53
A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology (2009) 1.52
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol (2005) 1.49
Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Exp Cell Res (2002) 1.48
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res (2008) 1.47
Efficacy of different technical procedures for sentinel lymph node biopsy in gastric cancer staging. Ann Surg Oncol (2007) 1.46
Response to preoperative short-course radiotherapy in locally advanced rectal cancer: value of f-fluorodeoxyglucose positron emission tomography. Onkologie (2008) 1.46
Identification of early molecular markers for breast cancer. Mol Cancer (2011) 1.45
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther (2011) 1.45
Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc Natl Acad Sci U S A (2011) 1.45
Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem (2002) 1.43
Treatment of thoracic anastomotic leaks after esophagectomy with self-expanding plastic stents. Ann Surg (2004) 1.35
Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells (2010) 1.35
Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther (2005) 1.33
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32
Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol (2006) 1.31
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res (2005) 1.28
Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res (2007) 1.28
MACC1 controls Met: what a difference an Sp1 site makes. Cell Cycle (2009) 1.27
Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas. Phys Med Biol (2005) 1.26
In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer (2002) 1.26
Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients. Phys Med Biol (2005) 1.26
Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer. Ann Surg (2012) 1.25
Construct validity testing of a laparoscopic surgery simulator (Lap Mentor): evaluation of surgical skill with a virtual laparoscopic training simulator. Surg Endosc (2007) 1.24
Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer (2009) 1.20
ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2. Oncogene (2004) 1.19
Differential involvement of vascular endothelial growth factor in the survival of hypoxic colon cancer cells. Cancer Res (2008) 1.18
Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res (2007) 1.17
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood (2002) 1.15
Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol (2006) 1.15
Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions. Opt Express (2009) 1.13
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet (2010) 1.12
New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues. J Med Chem (2008) 1.12
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst (2011) 1.11
Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther (2009) 1.11
MACC1 - more than metastasis? Facts and predictions about a novel gene. J Mol Med (Berl) (2009) 1.11
Scanning time-domain optical mammography: detection and characterization of breast tumors in vivo. Technol Cancer Res Treat (2005) 1.10
Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer (2002) 1.10
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg (2009) 1.10
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther (2005) 1.10
A high-throughput fluorescence-anisotropy screen that identifies small molecule inhibitors of the DNA binding of B-ZIP transcription factors. Anal Biochem (2005) 1.09
Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care (2010) 1.08
Sentinel node biopsy for the individualization of surgical strategy for cure of early-stage colon cancer. Ann Surg Oncol (2009) 1.08
Feasibility of navigated resection of liver tumors using multiplanar visualization of intraoperative 3-dimensional ultrasound data. Ann Surg (2007) 1.07
Functional haplotypes of the RET proto-oncogene promoter are associated with Hirschsprung disease (HSCR). Hum Mol Genet (2003) 1.07
Gastric cancer surgery in elderly patients. World J Surg (2006) 1.07
Circulating MACC1 transcripts in colorectal cancer patient plasma predict metastasis and prognosis. PLoS One (2012) 1.06
Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis. Neuro Oncol (2013) 1.05
High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer (2011) 1.04
Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica (2009) 1.03